기관내 튜브 시장

Market Overview
Endotracheal Tube Market size was valued at USD 539.4 million in 2022 and is estimated to reach at a compound annual growth rate (CAGR) of 6.00% over the forecast period 2023-2030.
An endotracheal tube is a flexible plastic tube that is placed through the mouth into the trachea which is connected to a ventilator to deliver oxygen to the lungs. The tube is inserted when a patient is unable to breathe on their own. The process of inserting the tube is called endotracheal intubation. Endotracheal tubes are mostly made of polyvinyl chloride (PVC) and can be used only once.
Endotracheal Tube Market Dynamics and Trends
The global endotracheal tube market is primarily driven by the increasing incidence of respiratory diseases such as pulmonary embolism, and chronic obstructive pulmonary disorders, and number of anesthesia activities during surgeries, etc., growing preference for anesthesia laryngeal masks over ETTs, the increasing need for intubation during severe injuries, and rising surgeries across the globe are the factors to drive the market in the forecast period.
The increasing prevalence of chronic respiratory diseases is expected to drive market growth.
According to the Centers for Disease Control and Prevention, chronic respiratory disorders (CRDs) impair the airways and other lung structures. Chronic obstructive pulmonary disease (COPD), asthma, occupational lung disorders, and pulmonary hypertension are some of the most frequent. Air pollution, occupational chemicals and dust, and repeated lower respiratory illnesses during childhood are also risk factors in addition to tobacco smoke. Asthma affects around 300 million individuals worldwide, which is more prevalent in industrialized countries such as the United States.
Additionally, according to the CDC's 2020 National Health Interview Surveys (NHIS), an estimated 25.2 million adults, including 4.2 million children, have asthma in the United States. In 2020, more than 10.3 million asthmatics, including approximately 1.8 million children, reported having one or more asthma attacks. Therefore, orotracheal intubation is preferred for asthmatic patients in acute respiratory distress. Thus, from the above statements, the market is expected to drive market growth.
The lack of skilled professionals for endotracheal intubation is expected to hamper the market growth.
Endotracheal tube procedures require highly skilled anesthetists and trained nurses. The lack of knowledge regarding the right choice of immediate treatment can adversely affect the patient’s condition, increase recovery time, and surge direct and indirect expenses. In emergency conditions, the improper diagnosis and treatment of serious injuries can cause deformities and lead to the dysfunction of the injured area or patient death. According to the WHO, it is estimated that around 70% of COPD patients are underdiagnosed owing to the lack of awareness about the disease. Like COPD, asthma is also highly underdiagnosed and undertreated (in around 50% of asthmatics). Thus these factors are hampering the market growth in the forecast period.
Moreover, the shortage of anesthetists and paramedics has become one of the key concerns for countries across the globe. The shortage has directly impacted the efficiency and capabilities of healthcare settings to provide surgical and emergency care, further hampering the demand for endotracheal tube devices used across these procedures.
COVID-19 Impact on Endotracheal Tube Market Growth
The COVID-19 epidemic had a positive impact on the endotracheal tube industry. The advent of COVID-19 has significantly increased the demand for endotracheal tubes, as breathing trouble is a clear indicator of infection, which has driven market growth. In the event of respiratory failure in COVID patients, the American Association for Bronchology and Interventional Pulmonology recommends conducting Open Surgical Tracheostomy (OST) or percutaneous dilatational tracheostomy. Moreover, the pandemic paved the way for emergency product approvals. For instance, a U.S.-based biotech firm, N8, secured emergency use authorization from Health Canada For its CeraSheild Endotracheal Tubes in mechanically ventilated COVID-19 patients. In addition, large private and public hospitals relatively have higher uptake of respiratory devices, and small hospitals and clinics have a low rate of product uptake. Thus, from the above statements, the market got driven in the forecast period.
Endotracheal Tube Market Segment and Shares
The ambulatory surgical centers (ASCs) segment is expected to hold the largest market share in endotracheal tube
The ambulatory surgical centers (ASCs) segment accounted for the largest market share in 2021. With rapid technological advancements in the healthcare sector, 60% of all surgeries can be performed at ambulatory surgical units, creating a surging demand for surgical procedures in emerging economies such as India. ASCs are expected to reduce the average cost of treatment by 70% when compared to the cost of inpatient surgery. This factor is important for a country like India, with 1.4 billion population, in which a significant number of people can earn less than $ 2 a day. Moreover, many Central government policies under the Ministry of Ayush facilitate people under the poverty line by providing them with medical insurance.
Additionally, in the U.S., Medicare is the largest single-payer of clinical services. Medicare spending accounts for more than 40% of the clinical expenditures of patients. Medicaid payments are divided into three main categories, the traditional home health benefit (mandatory), the personal healthcare option, and home and community-based waivers as an optional program. These three healthcare service categories collectively hold a small share of total Medicaid payments. Thus, from the above statements, the market segment accounted for the largest market share in the forecast period.
Endotracheal Tube Market Geographical Analysis
North America region holds the largest market share in the global endotracheal tube
North America region accounted for the largest market share in 2021. Over 40 million endotracheal intubations are performed annually in the U.S., making it the single largest interventional procedure. Nearly 2 million of those procedures are complex and challenging to perform. The LightSpeed Intubation System enables quicker and safer positioning of the endotracheal tube without losing control of the airway. Due to the high number of such cases, the demand for airway management devices is increasing globally.
Moreover, the presence of major regional players contributed to market growth. For instance, on January 14, 2020, Smiths Medical launched a new Polyvinyl Chloride (PVC) tracheostomy tube portfolio to its family of tracheostomy tubes. Smith’s Medical BLUselect tracheotomy tubes, BLUperc, and BLUgriggs percutaneous tracheostomy kits and trays. Additionally, many players in the market are developing products with antimicrobial and anti-coagulant coating properties that can reduce VAP. For instance, Medtronic Shiley Evac endotracheal tubes have been stated to reduce VAP by 50.0%. Thus, from the above statements, the North American region accounted for the largest market share in the forecast period.
Endotracheal Tube Companies and Competitive Landscape
Major key players in the endotracheal tube are ConvaTec Inc., Bactiguard AB, Teleflex Incorporated, and Medtronic Plc. (Covidien), Smiths Group plc. (Smiths Medical), ROYAX, S.R.O, Medline Industries, Inc., Eakin Healthcare Group(Armstrong Medical Ltd), Venner Medical and P3 Medical Limited
On January 20, 2022, P3 Medical is set to showcase a device designed to tighten infection control in airway management at Arab Health 2022. The NeVap Aspire Subglottic Suction Endotracheal tube (ASSET) is the only FDA-cleared multiport suction breathing tube. Clinicians have developed it to make mechanical ventilation safer by preventing the risks of ventilator-associated pneumonia.
Covidien:
Overview:
Covidien was an Irish-headquartered global healthcare product company and manufacturer of medical devices and supplies. Covidien became an independent publicly traded company after being spun off from Tyco International in 2007. Covidien's portfolio consists of medical devices, including surgical, respiratory, patient monitoring, gastrointestinal, lung health, and renal care products. The Medical Devices segment includes developing, manufacturing, and selling mechanical instruments, energy devices, soft tissue repair products, vascular products, oximetry and monitoring products, airway and ventilation products, and other medical products. In June 2014, Covidien plc was acquired by Medtronic for $42.9 billion in Cash and Stock. With its expanded portfolio of innovative products and services, this acquisition will allow Medtronic to reach more patients.
¬Product Portfolio:
Shiley Reinforced Oral/Nasal Endotracheal Tube: The Shiley oral/nasal endotracheal tube reinforced features a soft, flexible PVC tube with spiral-wound reinforcing wire designed to help reduce kinking.
The global endotracheal tube report would provide an access to approx. 45+market data table, 40+figures and 180pages.